a strong trendp = 0.055
In contrast, mutations in ASXL1 were more prevalent among newly diagnosed patients ( p = 0.04), and a strong trend for a higher prevalence of TET2 mutations among this cohort as well ( p = 0.055).
In contrast, mutations in ASXL1 were more prevalent among newly diagnosed patients ( p = 0.04), and a strong trend for a higher prevalence of TET2 mutations among this cohort as well ( p = 0.055).
A slight trend towards a higher frequency of lower VAFs was noted among patients with relapsed/refractory AML ( p = 0.09).